Investor Newsletter

Issue 08 2022

MicroPort®

MicroPort® Announces 2022 Interim Results

On 30 Aug, MicroPort Scientific Corporation (“MicroPort®” or the “Group”) announced the interim results of the Group and its subsidiaries for the six months ended 30 June 2022 (the "Reporting Period"). In the first half of 2022, the Group continued to maintain stable business operations and steady development, and achieved global business revenue of US$405.0 million, representing an increase of 10.1% compared to the corresponding period last year. Within this, the heart valve business, the endovascular and peripheral vascular devices business, and the neurovascular devices business recorded increase of 44.8%, 26.6% and 22.9% in revenue respectively, mainly attributable to the rapid market penetration and the revenue contributed from new products. Meanwhile, the overseas revenue of the CRM business, the orthopedics devices business and the cardiovascular devices business recorded steady growth of 8.1%, 9.7%, and 28.1% respectively.

During the reporting period, in the face of the sudden outbreak of the omicron variant of COVID-19 in Shanghai and other cities, the Group made full use of the platform advantages of a globalized supply chain and full business coverage, ensuring the continuous operation of the production bases and the supply of core products, which demonstrated its commitment to social responsibility and caring for people’s livelihood with its principle of “patients come first”. The Group is committed to continuously bringing innovation, techonology and services to patients around the world, and building a global leading medical devices group in the high-tech medical field.

During the reporting period, the R&D projects of the Group achieved fruitful results. From the beginning of 2022 to the date of this announcement, the Group and its associated companies have had 14 products obtain the Class III initial registration certificates from the NMPA, and have obtained FDA clearance for 5 products and CE Marking for 5 products. Meanwhile, our self-developed product, the prostatic urethral lift system, was newly admitted in the Green Path. At the date of this announcement, the Group and its associated companies had a total of 26 products being approved to enter the Green Path, ranking them first in the medical device industry for seven consecutive years.



Endovastec™ Announces 2022 Interim Results

On 25 Aug, Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. ("Endovastec™") announced the interim results of the Company and its subsidiaries for the six months ended 30 June 2022 (the "Reporting Period"). During the reporting period, Endovastec™ recorded revenue of RMB 459 million, representing an increase of 26.64% compared to the corresponding period of last year. Net profit attributable to shareholders of the listed company was RMB 215 million, increased by 16.42% on year-on-year basis. Net profit excluding non-recurring gains and losses was RMB 205 million with a 13.86% increase. In the face of recurring outbreaks of COVID-19 in some cities in China, Endovastec™ overcame multiple difficulties in the first half of 2022 and continued to maintain good momentum with regard to its operations.

Mr Qing Zhu, President of Endovastec™, stated:
"In the first half of 2022, intermittent outbreaks of COVID-19 in China had a short-term impact on our business. However, with the joint efforts of our employees, Endovastec™ actively carried out various prevention and control efforts against the pandemic while we steadily advance our operation in an orderly manner, ensuring sustained and rapid growth.
In the future, we will further accelerate the pace of development and continue to strive to achieve the ambitious vision of building a world-leading group of emerging medical technologies in the field of aortic and peripheral vascular intervention."

CardioFlow Medtech
Announces 2022 Interim Results

On 29 Aug, MicroPort CardioFlow Medtech Corporation ("CardioFlow Medtech") announced the interim results of the Company and its subsidiaries for the six months ended 30 June, 2022 ("Reporting Period").During the reporting period, CardioFlow Medtech recorded revenue of RMB 124.8 million, representing an increase of 44.8% compared to the corresponding period last year. The gross profit margin also improved steadily by 8.6 percentage points to 63.7% on a year-on-year basis.

CardioFlow Medtech's sales revenue continues to grow primarily as a result of the increased market recognition and sales volume of two commercialized products, the VitaFlow® transcatheter aortic valve implantation (TAVI) and delivery system ("VitaFlow®") and the new generation VitaFlow Liberty™ transcatheter aortic valve and retrievable delivery system ("VitaFlow Liberty™"). And the growth of the gross profit margin was mainly attributable to our continuous efforts to reduce the cost of procuring raw materials through the global supply chain and our achievements in cost-saving through economies of scale.

Mr Guoming Chen, the Executive Director and President of CardioFlow Medtech, said, “in the first half of 2022, CardioFlow Medtech forged ahead and achieved sustained and robust revenue growth and gross profit margin improvement, despite the challenges of the pandemic and increasingly fierce market competition. We will continue to rely on the extraordinary product advantages, the unremitting development of the Total Solutions team and the abundant resources of MicroPort® Group, to further expand the domestic market share, and accelerate the pace of overseas development, to achieve the long-term sustainable development of CardioFlow Medtech. We will continue to use our years of R&D experience and technological foundation to provide high-quality and innovative products for physicians and patients around the world.”

MicroPort NeuroTech™ Announces 2022 Interim Results

On 27 Aug, MicroPort NeuroTech Limited ("MicroPort NeuroTech™" or the "Company") announced the interim results of the Company and its subsidiaries for the six months ended 30 June 2022 (the "Reporting Period"). This is the first interim performance report released by MicroPort NeuroTech™ since it was successfully listed on the main board of the Hong Kong Stock Exchange on July 15, 2022.

During the reporting period, MicroPort NeuroTech™ achieved revenue of RMB 206 million, representing an increase of 22.9% compared to the corresponding period of last year, of which international (non-China) operations recorded revenue of RMB 11.80 million for the first time. The growth in revenue was mainly due to the commercialization of NUMEN™ Coil Embolization System ("NUMEN™ Coil") in the United States, South Korea, and Europe; the rapid increase in clinical usage of innovative products approved in recent years, including NUMEN™ Coil, Bridge™ Vertebral Artery Drug-eluting Stent ("Bridge™ Stent") and U-track™ Intracranial Support Catheter ("U-track™ Support Catheter"); and the steady increase in sales volume of the market-leading products including the Tubridge™ Flow-diverting Stent ("Tubridge™ Stent") and Asahi™ Neurovascular Guidewires ("Asahi™ Guidewires").

Mr Zhiyong Xie, President of MicroPort NeuroTech™ stated: "In the first half of 2022, the outbreaks of COVID-19 in some regions challenged the Company operation in many aspects including supply chain, R&D and marketing promotion. In order to ensure the clinical operation carried out normally and the production and delivery competed orderly, all functions in MicroPort NeuroTech™ worked together to promote the resumption in a planned way under the leadership of the Board and management team, formulate an emergency plan for pandemic prevention and control, and guarantee the Company can operate stably in the face of uncertain external environment. In the future, MicroPort NeuroTech™ will further accelerate the progress of R&D and industrialization to provide total healthcare solutions that can prolong and reshape the lives of patients with the cerebrovascular disease globally."

MicroPort® MedBot™ Announces 2022 Interim Results

On 26 Aug, Shanghai MicroPort MedBot (Group) Co., Ltd. ("MicroPort® MedBot™") announced the interim results of the Company and its subsidiaries for the six months ended 30 June 2022 (the "Reporting Period"). In the first half of 2022, the recurrence of COVID-19 in China has brought severe challenges to the Company. MicroPort® MedBot™ worked against the clock to allocate its resources and focused on ensuring the orderly resumption of production and operation, maintained stable progress on the research and development, clinical trials and commercialization of surgical robot products.

Dr Chao He, Executive Director & President of MicroPort® MedBot™ stated: "Despite the challenges including the recurrence of COVID-19 and the conflict of international relations, MicroPort® MedBot™'s over 1,200 employees uphold the idea of innovation, passion, group wisdom and tenacity, explore and proceed in adversity, made gratifying breakthrough in fields including products innovation and commercialization. Since MicroPort® MedBot™ has been listed on the Hong Kong Stock Exchange in November 2021, every step of our development has revived warm care from our investors. We will continue to work hard to promote the development of innovative products based on the five 'golden specialties', fulfill our commitment to meeting the frontier demand for minimally-invasive surgery, build a globalized medical robots total solution innovation platform, realize the initial vision of making surgeries easy anywhere, and live up to the support and high expectations of all sectors of society."

MEDBOT™ 微创机器人

MicroPort®

MicroPort EP Listed on the SSE STAR Market

On 31 Aug, Shanghai MicroPort EP Medtech Co., Ltd. (688351.SH, "MicroPort EP" or the "Company"), a global medical device company in the field of electrophysiological interventional diagnosis and ablation therapy and a joint-stock company of MicroPort Scientific Corporation, announced it has successfully listed on the STAR Board of Shanghai Stock Exchange ("SSE STAR Market"). MicroPort EP became the first company listed under the "Guidelines of Shanghai Stock Exchange for the Application of the Rules for Issuance and Listing Review on the STAR Market No. 7 – Medical Device Companies under the Fifth Set of Listing Standards" published and implemented on June 10, 2022.

Dr Yiyong Sun, President of MicroPort EP, stated: "The field of electrophysiology features high technical standards and cross-disciplinary collaboration and relies heavily on the advancement of biomedical technology, materials technology, electronic information engineering, and other technologies. As a company that has always placed great importance on the deep integration of scientific and technological achievements into industrial applications, MicroPort EP will continue to dive deep into this field for technological breakthroughs, improve its product performance, and actively promote the broader availability and application of its products. MicroPort EP will also actively implement China's hierarchical diagnosis and treatment system, and continue to help primary hospitals improve their EP diagnosis and treatment quality as a way to support the development EP industry in China.""The listing of MicroPort EP on the STAR Market makes it the first medical device company to have been approved under the fifth set of STAR Market listing guidelines. It provides a better platform for our future development and allows us to better contribute to the development of the medical device industry around the world," commented Dr Qiyi Luo, Chief Technology Officer of MicroPort® and Chairman of MicroPort EP, "With the support of the capital market, we will be able to further promote innovation and develop world-leading products with excellent quality," he added.

Mr Zheyi Gu, Chairman of MicroPort EP, commented: "We should not only strive to develop the domestic market, but also embrace a global vision and aspire to serve the broader global market well. MicroPort EP has always been an industry leader in China in terms of going global. In the future, we will further accelerate our strategic development of internationalization, strengthen the global sales network, continuously improve our brand awareness globally, and strive to become an international medical device company serving the world as it takes root in China."



VitaFlow Liberty™ by CardioFlow Medtech Obtains Marketing Approval in Colombia

MicroPort CardioFlow Medtech Corporation ("CardioFlow Medtech") recently announced that its independently-developed transcatheter aortic valve implantation (TAVI) solution, the new-generation VitaFlow Liberty™ Transcatheter Aortic Valve and Retrievable Delivery System ("VitaFlow Liberty™") has received marketing approval from the National Institute for Drug and Food Surveillance of Colombia.

In the future, CardioFlow Medtech will continue to accelerate the commercialization of innovative products with international competitiveness and introduce TAVI products to more countries and regions, bringing high-quality, universal total solutions for structural heart disease to more patients around the world.

MicroPort™

MicroPort NeuroTech™ NUMEN Coil Embolization System Receives Marketing Approval in Japan

MicroPort Neurotech Limited ("MicroPort NeuroTech™"), a pioneering Chinese company in the field of neurovascular interventional treatment, announced that it has received marketing approval issued by Ministry of Health, Labour and Welfare Japan for its independently-developed Numen™ Coil Embolization System ("Numen™"), marking the first approved product in Japan for MicroPort NeuroTech™.

The approval of NUMEN™ in the Japanese market represents yet another milestone in the globalization strategy for emerging markets. In the future, MicroPort NeuroTech™ will continue to strengthen in-depth cooperation with overseas clinical experts and provide top-quality and more accessible and comprehensive medical solutions to stroke patients worldwide.

MicroPort

MicroPort NeuroTech™ Completes First Implantations of NUMEN™ Coil Embolization System in Poland

MicroPort Neurotech Limited ("MicroPort NeuroTech™") recently announced that its independently developed Numen™ Coil Embolization System ("Numen™") has been successfully used in the first two implantations in Poland. Numen™'s pushability and detachability were highly appreciated by the physicians.

Cerebral aneurysms are mostly abnormal bulges in the walls of intracranial arteries. The possibility of aneurysm rupture increases over time, and intracranial aneurysms are known as "time bomb in the head" due to their high mortality and morbidity rate upon rupture. Coil embolization is one of the most important methods of intracranial aneurysm treatment. The first two implantations of NUMEN™ in Poland signal the rapid penetration of MicroPort NeuroTech™ products into the EU market. In the future, MicroPort NeuroTech™ will continue to strengthen in-depth cooperation with overseas clinical experts and provide top-quality and more accessible and comprehensive medical solutions to stroke patients worldwide.

MicroPort

MicroPort NeuroTech™ APOLLO™ Intracranial Arterial Stent System Completed First Implantation in Brazil

MicroPort Neurotech Limited ("MicroPort NeuroTech™"), recently announced that its independently developed APOLLO™ Intracranial Arterial Stent System ("APOLLO™") has been implanted in a patient in Brazil, which marks its first application in the country as well as in any overseas market outside China.

The clinical implantation of APOLLO™ in Brazil is the first time it enters an overseas market. This means the ischemic products of MicroPort NeuroTech™ have been further recognized by the overseas market. In the future, MicroPort NeuroTech™ will continue to strengthen in-depth cooperation with global clinical experts and provide more patients worldwide with better and more inclusive medical solutions for total stroke resolution.

MicroPort® MedBot™ JV's R-ONE™ Vascular Interventional Surgical Robot Completes Registration Clinical Trial

Cathbot (Shanghai) Robot Co., Ltd. ("Shanghai Cathbot™"), a joint venture between Shanghai MicroPort MedBot (Group) Co., Ltd. ("MicroPort® MedBot™") and French company Robocath S.A.S (Robocath), recently announced the completion of the clinical trial for R-ONE™, a vascular interventional surgical robot, making R-ONE™ the first robotic system for vascular intervention to have completed a multicenter clinical trial in China.

Dr Chao He, President of MicroPort® MedBot™, said: "The completion of the multicenter clinical trial for the R-ONE™ Vascular Interventional Surgical Robot is a major milestone for MicroPort® MedBot™ in the pan-vascular intervention field. It is of great significance in driving the development of more precise and intelligent vascular interventions. In the future, robots for vascular interventions will be equipped with 5G and AI technologies. They will accomplish more breakthroughs when combined with angiography and hemodynamic monitoring and other technologies. Meanwhile, with the advantage of group-based operation, MicroPort® MedBot™ will partner with more academic experts nationwide to promote high-quality medical resources to primary hospitals, and will provide more patients with precise, intelligent, and inclusive robotic surgical solutions."



Investor Newsletter

Issue 08 2022

MicroPort®

For more information, please contact:

Martin Sun
Chief Financial Officer
MicroPort Scientific Corporation
Tel: (86)(21) 38954600
Email: ir@microport.com

Leanne Li
Board Secretary & VP of Securities Affairs
MicroPort Scientific Corporation
Tel: (86)(21) 38954600
Email: ir@microport.com